SARS CoV 2 Infection
82
6
15
41
Key Insights
Highlights
Success Rate
95% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
2.4%
2 terminated out of 82 trials
95.3%
+8.8% vs benchmark
7%
6 trials in Phase 3/4
15%
6 of 41 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 41 completed trials
Clinical Trials (82)
Clinical Validation of the NowFuture Digital Flu / COVID Test in Anterior Nasal Samples for Over-the-Counter (OTC) Use in Australia
Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome
Expression of Inflammatory Markers in the Course of Acute Respiratory Viral Infections
CU-COMMITS: COVID-19 Care in Black and Latino Communities and Households. Clinical and Molecular Outcomes of SARS-CoV-2
Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States
NIH RECOVER Tissue Pathology: Understanding the Long-Term Impact of COVID-19
COVID-19 Transmission and Morbidity in Malawi
Transplacental Transmission of RSV (TTRSV)
CARE-ID: Dynamics of Respiratory Infections in Children and Transmission in Households and Schools
Pancoronavirus Vaccine Study in Healthy Adults
Exercise in Child Health
Open-label, Multi-centre, Non-Inferiority Study of Safety and Immunogenicity of BIMERVAX for the Prevention of COVID-19 in Adolescents From 12 Years to Less Than 18 Years of Age.
Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda
The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection
Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS
Development and Validation of (Bio)Sensors for the Identification of Pathogens
Phase II Study of AVX/COVID-12 Vaccine in Subjects With Prior SARS-CoV-2 Immunity Evidence
Safety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients
A Phase IIb/III Clinical Trial to Assess Safety and Immunogenicity of a COVID-19 Vaccine Booster Dose in Immunosupressed Adults.
Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2